Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East

INTERNATIONAL JOURNAL OF CARDIOLOGY

卷:225

Review

Al Sayed, Nasreen¹  Al Waili, Khalid²  Alawadi, Fatheya³  Al-Ghamdi, Saeed⁴  Al Mahmeed, Wael⁵  Al-Nouri, Fahad⁶  Al Rukhaimi, Mona⁷  Al-Rasadi, Khalid⁸  Awan, Zuhier⁹  Farghaly, Mohamed⁷  Hassanein, Mohamed¹⁰  Sabbour, Hani¹¹  Zubaid, Mohammad¹²  Barter, Philip¹³ 

[1] Gulf Diabet Specialist Ctr, POB 21686, Manama, Bahrain

[2] Sultan Qaboos Univ Hosp, Dept Clin Biochem, POB 38, Muscat 123, Oman

[3] Dubai Hlth Author, Endocrine Dept, Dubai Hosp, Dubai, U Arab Emirates

[4] King Abdulaziz Univ Hosp, Dept Med, POB 80215, Jeddah 21589, Saudi Arabia

[5] Cleveland Clin, Inst Heart & Vasc, Abu Dhabi, U Arab Emirates

[6] Prince Sultan Cardiac Ctr, Cardiovasc Prevent Unit, Riyadh, Saudi Arabia

[7] Dubai Med Coll, POB 223331, Dubai, U Arab Emirates

[8] Sultan Qaboos Univ Hosp, Dept Biochem, POB 38, Muscat 123, Oman

[9] King Abdulaziz Univ, Jeddah 22254, Saudi Arabia

[10] Dubai Hosp, Dubai, U Arab Emirates

[11] Shaikh Khalifa Med City, Cardiac Sci Inst, Abu Dhabi, U Arab Emirates

[12] Kuwait Univ, Fac Med, Dept Med, Kuwait, Kuwait

[13] Univ New South Wales, Sch Med Sci, Sydney, NSW 2052, Australia

关键词: Cardiovascular disease;    Dyslipidaemia;    Guidelines;    Lipid disorder;    Middle East;   

DOI  :  10.1016/j.ijcard.2016.09.081

来源: Elsevier

【 摘 要 】

Background: Plasma lipid disorders are key risk factors for the development of atherosclerotic cardiovascular disease (ASCVD) and are prevalent in the Middle East, with rates increasing in recent decades. Despite this, no region-specific guidelines for managing plasma lipids exist and there is a lack of use of guidelines developed in other regions. Methods: A multidisciplinary panel of regional experts was convened to develop consensus clinical recommendations for the management of plasma lipids in the Middle East. The panel considered existing international guidelines and regional clinical experience to develop recommendations. Results: The panel's recommendations include plasma lipid screening, ASCVD risk calculation and treatment considerations. The panel recommend that plasma lipid levels should be measured in all at-risk patients and at regular intervals in all adults from the age of 20 years. A scoring system should be used to calculate ASCVD risk that includes known lipid and non-lipid risk factors. Primary treatment targets include low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. Lifestyle modifications should be first-line treatment for all patients; the first-line pharmacological treatment targeting plasma lipids in patients at moderate-to-high risk of ASCVD is statin therapy, with a number of adjunctive or second-line agents available. Guidance is also provided on the management of underlying conditions and special populations; of particular pertinence in the region are familial hypercholesterolaemia, diabetes and metabolic dyslipidaemia. Conclusions: These consensus clinical recommendations provide practicing clinicians with comprehensive, region-specific guidance to improve the detection and management of plasma lipid disorders in patients in the Middle East. (C) 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

【 授权许可】

Free